XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 28,450,373 $ 57,632,693
Short-term investments 106,082,989 105,357,277
Accounts receivable 10,365,950 7,333,059
Prepaid expenses and other current assets 1,188,042 917,257
Prepaid expenses and other current assets from affiliated entity 1,882,257 610,652
Total current assets 147,969,611 171,850,938
Fixed assets, net 8,700,628 7,306,695
Investment in affiliated entity- GeneOne 21,716,728 14,941,277
Investment in affiliated entity - PLS 5,309,488 5,045,915
Intangible assets, net 8,449,306 3,905,860
Goodwill 10,513,371 10,113,371
Other assets 1,326,317 676,803
Total assets 203,985,449 213,840,859
Current liabilities:    
Accounts payable and accrued expenses 12,707,754 13,064,899
Accounts payable and accrued expenses due to affiliated entity 600,969 165,047
Accrued clinical trial expenses 5,006,287 2,600,483
Common stock warrants 1,815,343 1,301,138
Deferred revenue 14,502,626 13,449,768
Deferred revenue from affiliated entity 469,792 504,442
Deferred rent 391,913 380,629
Total current liabilities 35,494,684 31,466,406
Deferred revenue, net of current portion 374,043 103,074
Deferred revenue from affiliated entity, net of current portion 274,194 677,371
Deferred rent, net of current portion 5,576,953 5,485,313
Deferred tax liabilities 175,642 175,642
Total liabilities 41,895,516 37,907,806
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 73,483 72,218
Additional paid-in capital 546,251,246 534,004,564
Accumulated deficit (387,845,427) (361,097,896)
Accumulated other comprehensive income 3,514,362 2,708,339
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 161,993,664 175,687,225
Non-controlling interest 96,269 245,828
Total stockholders’ equity 162,089,933 175,933,053
Total liabilities and stockholders’ equity $ 203,985,449 $ 213,840,859